Skip to Content

WPI 845 (Glipizide extended release 10 mg)

Pill imprint WPI 845 has been identified as Glipizide extended release 10 mg.

Glipizide is used in the treatment of diabetes, type 2 and belongs to the drug class sulfonylureas. Risk cannot be ruled out during pregnancy. Glipizide 10 mg is classified as a Schedule N controlled substance under the Controlled Substance Act (CSA).

Glipizide extended release 10 mg WPI 845
Glipizide extended release 10 mg WPI 845
Glipizide extended release 10 mg WPI 845
Glipizide extended release
WPI 845
10 mg
6.00 mm
Prescription only
Drug Class:
Pregnancy Category:
C - Risk cannot be ruled out
CSA Schedule:
N - Not a controlled drug
Watson Laboratories, Inc.
National Drug Code (NDC):
Inactive Ingredients:
acetyltributyl citrate
hydroxyethyl cellulose (2000 mpa.s at 1%)
hydroxypropyl cellulose (type h)
lactose monohydrate
magnesium stearate
methacrylic acid - methyl methacrylate copolymer (1:1)
polyethylene glycol
isopropyl alcohol
ferrosoferric oxide
butyl alcohol
propylene glycol
Other Manufacturers / Repackagers:
NDC CodeManufacturer / Repackager
68084-0112 Amerisource Health Services
00228-2900 Actavis Pharma, Inc.
54569-5548 A-S Medication Solutions, LLC (repackager)
54868-4988 Physicians Total Care Inc (repackager)
58016-0691 Southwood Pharmaceuticals Inc (repackager)
55887-0179 Diversified Healthcare Services Inc (repackager)
55289-0301 PDRX Pharmaceuticals Inc (repackager)

Note: Inactive ingredients may vary.

View Details Print Page Imprint Search

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Copyright 2015, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.